EC Microbiology

Usually, combination therapy is associated with a shorter time to blood sterilization than vancomycin monotherapy for persistent MRSA bacteremia. Here we report a case of a 71-year-old female patient who originally had high comorbidity and systemic complications (cardiac, kidney, and pulmonary diseases), and she previously had a bilateral total knee replacement. Recently, the patient admitted on the 4^th of January with sepsis, and MRSA was isolated from blood cultures drawn on the day of admission. The blood drawing on days 5, 9, 15, and 19, they remained positive for MRSA despite the monotherapy with vancomycin or linezolid. After 22 days, on the 26^th of January, the patient expired. This case report supports the idea that a combination of vancomycin with other antibiotics like rifampicin, fosfomycin and/or an aminoglycoside are of the utmost importance to prevent treatment failure and as salvage therapy for persistent and complicated MRSA bacteremia.

Keywords: MRSA Bacteremia; Vancomycin Monotherapy

1. Lowy FD. “Staphylococcus aureus infections”. The New England Journal of Medicine8 (1998): 520-532.
2. Humphreys H. “Staphylococcus aureus: the enduring pathogen in surgery”. Surgeon6 (2012): 357-360.
3. Lindsay JA. “Hospital-associated MRSA and antibiotic resistance-what have we learned from genomics?” International Journal of Medical Microbiology6 (2013): 318-323.
4. Otto M. “Community-associated MRSA: what makes them special?” International Journal of Medical Microbiology6-7 (2013): 324-330.
5. Thomas S., et al. “Community-associated methicillin-resistant Staphylococcus aureus infections in Aboriginal children attending hospital emergency departments in a regional area of New South Wales, Australia: a seven-year descriptive study”. Western Pacific Surveillance and Response Journal4 (2017): 6-12.
6. Wehrhahn MC., et al. “Clinical and laboratory features of invasive community-onset methicillin-resistant Staphylococcus aureus infection: a prospective case-control study”. European Journal of Clinical Microbiology and Infectious Diseases8 (2010): 1025-1033.
7. David MZ., et al. “Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections”. Clinical Infectious Diseases6 (2014): 798-807.
8. Perez G., et al. “Community-acquired Staphylococcus aureus bacteremia in children: a cohort study for 2010-2014”. Archivos Argentinos de Pediatria6 (2016): 508-513.
9. Lee AS., et al. “Methicillin-resistant Staphylococcus aureus”. Nature Reviews Disease Primers 4 (2018): 18033.
10. Turner NA., et al. “Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research”. Nature Reviews Microbiology4 (2019): 203-218.
11. Vestergaard M., et al. “Antibiotic resistance and the MRSA problem”. Microbiology Spectrum (2019).
12. You JHS., et al. “Complicated infections with methicillin-resistant Staphylococcus aureus in Hong Kong”. The Journal of Hospital Infection1 (2011): 71-72.
13. Fabien Lamret., et al. “Antibiotic Tolerance of Staphylococcus aureus Biofilm in Periprosthetic Joint Infections and Antibiofilm Strategies”. Antibiotics9 (2020): 547.
14. Mark Wilcox., et al. “Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus: consensus by an International Working Group”. Future Microbiology4 (2019): 345-352.
15. S Al-Obeid., et al. “First Detection of an Invasive Staphylococcus aureus Strain (D958) with Reduced Susceptibility to Glycopeptides in Saudi Arabia”. Journal of Clinical Microbiology6 (2010): 2199-2204.
16. Harris SR., et al. “Evolution of MRSA during hospital transmission and intercontinental spread”. Science5964 (2010): 469-474.
17. Coombs GW., et al. “Evolution and diversity of community-associated methicillin-resistant Staphylococcus aureus in a geographical region”. BMC Microbiology1 (2011): 215.
18. McConoughey SJ., et al. “Biofilms in periprosthetic orthopedic infections”. Future Microbiology8 (2014): 987-1007.
19. Thurlow LR., et al. “Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo”. Journal of Immunology11 (2011): 6585-6596.
20. Werdan K., et al. “Mechanisms of infective endocarditis: pathogen-host interaction and risk states”. Nature Reviews Cardiology1 (2014): 35-50.
21. Giovanni Cimmino., et al. “Changing Epidemiology, Improving Diagnostic Tools, and Centering the Patient for Up-to-Date Management”. Life 13 (2023): 377.
22. Pramodini B Kale-Pradhan., et al. “Vancomycin Treatment Failures for MRSA Bacteraemia Based on MIC Determined by E-test” (2015).
23. Alessandra Oliva., et al. “Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin”. Frontiers in Microbiology (2021).
24. Patcharasarn Linasmita MD. “Successful Management of Methicillin-Resistant Staphylococcus aureus Bacteraemia Unresponsive to Vancomycin by Adding Fosfomycin: A Case Report”. Journal of the Medical Association of Thailand7 (2012): 960-963.
25. Paul O Lewis PharmD., et al. “Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteremia”. Journal of Clinical Pharmacy and Therapeutics 43 (2018): 614-625.